Subscribe to our Newsletters !!


    COVID-19 antibody chase warms up universally, still no assurance

    Many individuals are focusing in nations over the world to be infused with test antibodies that may stop COVID-19, prodding trust possibly ridiculous that a conclusion to the pandemic may show up sooner than foreseen. Around 100 research bunches are seeking after immunizations with about twelve in beginning times of human preliminaries or ready to

    Adage and Pfizer knock up Amplyx’s series C to top $90 million

    Amplyx Pharmaceuticals, a biotech organization creating imaginative treatments for incapacitating and perilous sicknesses in patients with traded off insusceptible frameworks, today reported that it has shut a $53 million Series C augmentation, which brings the Series C round to over $90 million. The financing was driven by Sofinnova Investments, with support from existing speculators including

    Rundown of WHO’s main 8 contenders for COVID-19 antibody

    Five months into the worldwide flare-up of COVID-19, the world is attempting to beat the clock to set up an antibody for treating coronavirus patients. World Health Organisation(WHO) has recognized top eight contender for the coronavirus antibody: CanSino Biological Inc/Beijing Institute of Biotechnology: The Chinese antibody has been named as a top contender by WHO.

    US signs contract with Pfizer for COVID-19 antibody dosages

    Wellbeing and Human Services Secretary Alex Azar declared on Wednesday that the US has marked an agreement with Pfizer for conveyance in December of the initial 100 million dosages of a COVID-19 antibody the pharmaceutical organization is attempting to create. The US could purchase another 500 million portions under the understanding, Azar said. “Presently those

    Pfizer changes convention for virus vaccine: study

    Drugmaker Pfizer has modified the protocol for its late-stage study of its vaccine against the new coronavirus, this time to include more young participants. The company said on Monday that it’s received permission from the Food and Drug Administration to include adolescents aged 12 through 15 in its global COVID-19 vaccine study. New York-based Pfizer

    India needs Pfizer to do nearby examination for approval: Official

    Any vaccine manufacturer, such as Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must run a neighborhood”bridging” safety and immunogenicity study to be considered for the country’s immunisation programme, a senior government official told Reuters. Serum Institute of India, the local maker of the vaccine developed by AstraZeneca Plc and